Venous Thromboembolism » Cancer Associated Thrombosis

Abstract Number: PB0933

A randomized clinical trial to evaluate the effect of rosuvastatin with enoxaparin on circulating tissue factor extracellular vesicles following ovarian cancer surgery

A. Osataphan¹, R. Patell², R. Rosovsky³, P. Elavalakanar¹, A. Bregar⁴, A. Ramos⁴, L. Garrett¹, S. Ren⁵, D. Neuberg⁵, M. Shea¹, J. Zwicker²

Abstract Number: PB0927

Abelacimab does not influence the effects of two commonly used antiplatelet agents in vitro

Y. Khder¹, S. Cote², P. Hoffmann³, D. Bloomfield⁴

Abstract Number: PB0925

Abelacimab has no effect on platelet aggregation induced by TRAP-6 and collagen

Y. Khder¹, S. Cote², P. Hoffmann³, D. Bloomfield⁴

Abstract Number: VPB0944

Anticoagulant associated bleeding risk assessment model for cancer associated thrombosis patients: A systematic review

G. POENOU¹, E. TOLEDANO², H. HELFER³, L. PLAISANCE², e. VERSINI², N. DIAB⁴, S. DJENNAOUI², I. Mahe⁵

Abstract Number: PB0914

Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer

C. Englisch¹, O. Königsbrügge², F. Moik³, P. Quehenberger⁴, M. Preusser⁵, I. Pabinger⁶, C. Ay⁶

Abstract Number: VPB0942

Association between RET and BRAF(V600) oncogenic status and risk of venous and pulmonary thromboembolism in patients with papillary thyroid cancer

D. Katalinic¹, I. Aleric², A. Vcev², M. Solter³, L. Toetome⁴

Abstract Number: OC 16.5

Available Risk Scores Modestly Predict Hemorrhage in Patients with Cancer-Associated Thrombosis (CAT)

K. Sanfilippo¹, S. Luo², B. Gage³

Abstract Number: VPB0940

Biomarkers of coagulopathy in patients with different types of acute leukemia

Y. Hisada¹, S. Archibald¹, K. Bansal², S. Dwarampudi², A. Mullen², S. Bhatia², R. Bhatia², N. Mackman¹, R. Gangaraju²

Abstract Number: PB0908

Bleeding versus thrombosis: Case series on dilemma of VTE management in cancer patients and role of radiotherapy

A. Bolarinwa, O. Popoola, M. Elebute

Abstract Number: OC 25.2

Cabozantinib Safety with Different Anticoagulants in Patients With Renal Cell Carcinoma (RCC)

A. Mesleh Shayeb¹, H. Dzimitrowicz², D. Urman¹, N. Dizman³, L. Meza³, A. Sivakumar⁴, C. Gan⁵, T. Zhang², P. Barata⁶, M. Bilen⁴, X. Gao⁷, D. Heng⁵, S. Pal³, M. Kaymakcalan⁸, B. McGregor⁸, T. Choueiri⁸, R. Mckay¹

Abstract Number: PB0930

Cancer associated thrombosis on bevacizumab: risk of recurrence and bleeding if bevacizumab is stopped or continued

M. Mayenga¹, N. Falvo², I. MAHɳ, A. Jannot⁴, B. Gazeau⁵, G. Meyer⁶, O. Sanchez⁷, B. Planquette⁴

Abstract Number: OC 32.5

CD146-positive tumors are associated with venous thromboembolism

A. Joshkon¹, J. Stalin¹, W. Traboulsi¹, L. Vivancos -Stalin¹, M. Nollet¹, R. Lacroix², R. Bachelier¹, F. Dignat-George³, A. Bertaud¹, A. leroyer¹, N. Bardin³, M. Blot-Chabaud¹

Abstract Number: VPB0946

Clinical Impact of Thromboprophylaxis in Pancreatic Cancer Patients: data from ACT4CAT study

N. Tsoukalas, A. Christopoulou, E. Timotheadou, I. Athanasiadis, A. Koumarianou, S. Peroukidis, G. Samelis, A. Psyrri, N. Kapodistrias, A. Nikolakopoulos, C. Andreadis, A. Ardavanis, E. Samantas, C. Papandreou, D. Mavroudis, A. Bokas, V. Barbounis, A. Athanasiadis, P. Papakotoulas, I. Boukovinas

Abstract Number: PB0929

Comparison between full dose and reduced dose enoxaparin in the management of cancer-associated venous thromboembolism

J. Ong¹, E. Leitinger², S. Chunilal³

Abstract Number: PB0911

Comparison of effectiveness and safety of direct oral anticoagulant versus low molecular weight heparin treatment for venous thromboembolism in patients with active cancer – the OSCAR UK Study

A. Cohen¹, C. Wallenhorst², C. Becattini³, B. Schaefer⁴, K. Abdelgawwad⁴, G. Psaroudakis⁴, G. Brobert⁵, C. Coleman⁶, A. Ekbom⁷, C. Ay⁸, A. Lee⁹, A. Khorana¹⁰, M. Carrier¹¹, M. Rivera¹², C. Marinez²

Abstract Number: PB0910

Comparison of standard vs low dose of direct oral anticoagulants for the secondary prophylaxis of venous thromboembolism in patients affected by hematologic malignancies

A. Serrao¹, M. Chavez Orellana², G. Assanto³, R. Mormile³, E. Baldacci³, C. Santoro⁴, A. Chistolini²

Abstract Number: PB0918

Comparison of the Khorana, PROTECHT and ONKOTEV risk assessment models to predict venous thromboembolism in patients with pancreatic cancer

C. Frere¹, L. Gauthier², C. Canivet³, S. Gourgou², L. Buscail³, B. Bournet³, D. Farge⁴

Abstract Number: OC 16.4

COMPASS versus Khorana Risk Assessment Model for Predicting Venous Thromboembolic Events in Patients with Non-Small Cell Lung Cancer on Active Treatment with Chemotherapy and Immunotherapy.

H. Abdel-Razeq¹, B. Sharaf¹, R. AlMasri², R. Bater¹, M. Abualsha'r¹, O. Salama¹, F. Tamimi¹, K. Ashouri¹, D. Abu Laban¹, T. Salameh¹, R. Al zughul¹, Y. Alhalaseh¹

Abstract Number: PB0905

D-dimer level measured at first incident cancer-related venous thromboembolism is a predictor for recurrence: a retrospective cohort study

H. Almajed¹, F. Aleidan²

Abstract Number: PB0928

Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Patients with Hematological Malignancies

R. Robinson¹, G. Spectre², M. Lishner³, O. Sharabi⁴, E. Robinson⁵, O. Hamburger Avnery⁶, A. Gafter-Gvili⁷, P. Raanani², A. Leader⁸